Decoding Pulmonary Embolism: Pathophysiology, Diagnosis, and Treatment

peer-reviewed

dc.contributor.author
Peracaula Domínguez, Míriam
dc.contributor.author
Sebastián, Laura
dc.contributor.author
Francisco Albesa, Iria
dc.contributor.author
Bonnin Vilaplana, Marc
dc.contributor.author
Rodriguez Chiaradía, Diego A.
dc.contributor.author
Tura-Ceide, Olga
dc.date.accessioned
2025-03-12T09:29:52Z
dc.date.available
2025-03-12T09:29:52Z
dc.date.issued
2024-08-23
dc.identifier
http://hdl.handle.net/10256/26550
dc.identifier
39335450
dc.identifier
PMC11428250
dc.identifier.uri
https://hdl.handle.net/10256/26550
dc.description.abstract
Pulmonary Embolism (PE) is a life-threatening condition initiated by the presence of blood clots in the pulmonary arteries, leading to severe morbidity and mortality. Underlying mechanisms involve endothelial dysfunction, including impaired blood flow regulation, a pro-thrombotic state, inflammation, heightened oxidative stress, and altered vascular remodeling. These mechanisms contribute to vascular diseases stemming from PE, such as recurrent thromboembolism, chronic thromboembolic pulmonary hypertension, post-thrombotic syndrome, right heart failure, and cardiogenic shock. Detailing key risk factors and utilizing hemodynamic stability-based categorization, the review aims for precise risk stratification by applying established diagnostic tools and scoring systems. This article explores both conventional and emerging biomarkers as potential diagnostic tools. Additionally, by synthesizing existing knowledge, it provides a comprehensive outlook of the current enhanced PE management and preventive strategies. The conclusion underscores the need for future research to improve diagnostic accuracy and therapeutic effectiveness in PE
dc.description.abstract
This study has been funded by Institute of Health Carlos III through the Miguel Servet type grants CP17/00114, CPII22/00006 (Co-funded by European Social Fund " Investing in your future), The Spanish Society of Respiratory Medicine (SEPAR2019), Catalan Society of Pneumology (SOCAP2019), and from the Institute of Health Carlos III (PI21/01212, PI22/00133), and Spanish Society of Cardiology (SEC/FEC-INV-BAS 23/06). M. Peracaula was a recipient of Institute of Health Carlos III grant (FI22/00133). Cofunding was provided by the Fondo Europeo de Desarrollo Regional (FEDER); “Una manera de hacer Europa”
dc.format
application/pdf
dc.language
eng
dc.relation
info:eu-repo/semantics/altIdentifier/doi/10.3390/biomedicines12091936
dc.relation
info:eu-repo/semantics/altIdentifier/eissn/2227-9059
dc.rights
Reconeixement 4.0 Internacional
dc.rights
http://creativecommons.org/licenses/by/4.0
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Biomedicines, 2024, vol. 12, núm. 9, p. 1936
dc.source
Articles publicats (D-CM)
dc.source
Peracaula Domínguez, Míriam Sebastián, Laura Francisco Albesa, Iria Bonnin Vilaplana, Marc Rodriguez Chiaradía, Diego A. ura Ceide, Olga 2024 Decoding Pulmonary Embolism: Pathophysiology, Diagnosis, and Treatment Biomedicines 12 9 1936
dc.subject
Embòlia pulmonar
dc.subject
Pulmonary embolism
dc.subject
Sistema cardiovascular -- Malalties
dc.subject
Cardiovascular system -- Diseases
dc.subject
Teràpia trombolítica
dc.subject
Thrombolytic therapy
dc.title
Decoding Pulmonary Embolism: Pathophysiology, Diagnosis, and Treatment
dc.title
peer-reviewed
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.